DuPont Industrial Biosciences USA, LLC

DuPont Industrial Biosciences USA, LLC has been granted 36 US utility patents between 2019 and 2025, placing DuPont Industrial Biosciences USA, LLC at rank #8,785 across all assignees tracked by PlainPatent. This portfolio spans 37 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.8 claims per patent with primary concentration in C08B (POLYSACCHARIDES; DERIVATIVES THEREOF). As a US Corporation, DuPont Industrial Biosciences USA, LLC is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 44.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 33 grants, compared with 3 in the 2015–2019 window — a +1000% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. DuPont Industrial Biosciences USA, LLC's 17.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 37 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark DuPont Industrial Biosciences USA, LLC against peers pursuing similar technology classes.